As 2020 draws to a close, the team at TheraeutAix has been looking back and reflecting on the last 12…
In the first blog of this series1, we highlighted that, despite the potential advantages, there appear to be only a…
Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib,…
As part of a three-part series, we are looking at targeted delivery in idiopathic pulmonary fibrosis (IPF). This week, we…
Following a recent collaboration, TherapeutAix is delighted to announce the addition of Alderley Analytical and Peak Proteins as network partners.…